These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 39209452)

  • 1. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study.
    Feng T; Li Q; Zhu R; Yu C; Xu L; Ying L; Wang C; Xu W; Wang J; Zhu J; Huang M; Xu C; Jin J; Zhang X; Lu T; Yang Y; Zhu C; Chen Q; Su D
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39209452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
    Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
    EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study.
    Wang R; Wen S; Du X; Xia J; Hu B; Zhang Y; Zhou G; Jiang F; Lu X; Zhu M; Xu X; Shen B
    Cancer Med; 2024 Sep; 13(17):e70228. PubMed ID: 39275896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma.
    Wu C; Zhang G; Wang L; Hu J; Ju Z; Tao H; Li Q; Li J; Zhang W; Sheng J; Hou X; Hu Y
    Oncogene; 2024 Sep; 43(37):2751-2767. PubMed ID: 39122893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
    Xing W; Zhao L; Zheng Y; Liu B; Liu X; Li T; Zhang Y; Ma B; Yang Y; Shang Y; Fu X; Liang G; Yuan D; Qu J; Chai X; Zhang H; Wang Z; Lin H; Liu L; Ren X; Zhang J; Gao Q
    Front Immunol; 2021; 12():772450. PubMed ID: 34938292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
    He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
    Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
    Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
    Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.
    Kong Y; Su M; Fang J; Chen M; Zheng C; Jiang Y; Tao K; Wang C; Qiu G; Ji Y; Wang Y; Yang Y
    Sci Rep; 2024 Jul; 14(1):16495. PubMed ID: 39019976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
    BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
    Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
    Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.
    Chen YY; Wang PP; Hu Y; Yuan Y; Yang YS; Shi HS; Hao Q; Lin Z; Tian JF; Zheng Y; Liu T; Lin PP; Xu H; Ma XL; Yang L; Ding ZY
    Br J Cancer; 2024 Oct; 131(7):1126-1136. PubMed ID: 39164491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study.
    Wang J; Zhang J; Gao J; Zhao M; Ma Z
    Adv Clin Exp Med; 2024 Jun; 33(6):573-581. PubMed ID: 37676100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
    Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
    Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
    Qin J; Xue L; Hao A; Guo X; Jiang T; Ni Y; Liu S; Chen Y; Jiang H; Zhang C; Kang M; Lin J; Li H; Li C; Tian H; Li L; Fu J; Zhang Y; Ma J; Wang X; Fu M; Yang H; Yang Z; Han Y; Chen L; Tan L; Dai T; Liao Y; Zhang W; Li B; Chen Q; Guo S; Qi Y; Wei L; Li Z; Tian Z; Kang X; Zhang R; Li Y; Wang Z; Chen X; Hou Z; Zheng R; Zhu W; He J; Li Y
    Nat Med; 2024 Sep; 30(9):2549-2557. PubMed ID: 38956195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoimmunotherapy was associated with better short-term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy.
    Duan X; Zhao F; Shang X; Yue J; Chen C; Ma Z; Chen Z; Zhang C; Pang Q; Zhang W; Abbas AE; Jiang H
    Cancer Med; 2024 Aug; 13(15):e70113. PubMed ID: 39136674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
    Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
    J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
    Liu J; Chen H; Qiao G; Zhang JT; Zhang S; Zhu C; Chen Y; Tang J; Li W; Wang S; Tian H; Chen Z; Ma D; Tian J; Wu YL
    Cancer Immunol Immunother; 2023 Apr; 72(4):881-893. PubMed ID: 36121452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.